Siga Technologies (SIGA) Research & Development (2010 - 2025)
Siga Technologies' (SIGA) quarterly Research & Development came in at $7.1 million in Q3 2025, up 133.22% on a YoY basis from $3.0 million in Q3 2024, and up 60.39% quarter-over-quarter from $4.4 million in Q2 2025.
Analysis
Siga Technologies (SIGA) Research & Development (2010 - 2025) Analysis & Trends
Siga Technologies (SIGA) has reported Research & Development for 16 consecutive years, with $7.1 million the latest figure, recorded in Q3 2025.
- For the quarter ending Q3 2025, Research & Development rose 133.22% year-over-year to $7.1 million; the trailing twelve-month figure through Sep 2025 stood at $18.3 million (up 57.61% YoY), and the FY2024 full-year result was $12.3 million, down 25.06% from the prior year.
- Research & Development improved to $7.1 million in Q3 2025 per SIGA's latest filing, from $4.4 million in the prior quarter.
- Across five years, Research & Development topped out at $7.1 million in Q3 2025 and bottomed at $2.1 million in Q4 2021.
- Historically, Research & Development has averaged $4.0 million across 5 years, with a median of $3.5 million in 2025.
- The sharpest annual moves came in 2022 and 2023: Research & Development jumped 202.13% in 2022, then sank 59.14% in 2023.
- Over 5 years, Research & Development stood at $2.1 million in 2021, then soared by 199.29% to $6.4 million in 2022, then tumbled by 59.14% to $2.6 million in 2023, then gained by 27.74% to $3.3 million in 2024, then surged by 110.95% to $7.1 million in 2025.
- According to Business Quant data, Research & Development over the past three periods registered $7.1 million, $4.4 million, and $3.5 million for Q3 2025, Q2 2025, and Q1 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 643.26 Bn | 622.50 Bn | 17.26 Bn | 3.65 Bn |
| 2 | AbbVie | 443.31 Bn | 436.74 Bn | 12.70 Bn | 2.34 Bn |
| 3 | Merck | 364.74 Bn | 357.60 Bn | 12.21 Bn | 9.74 Bn |
| 4 | Novartis Ag | 266.46 Bn | 258.77 Bn | 11.24 Bn | -2.85 Bn |
| 5 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | 2.81 Bn |
| 6 | Sanofi | 52.33 Bn | 44.95 Bn | 10.79 Bn | -2.60 Bn |
| 7 | Revolution Medicines | 43.79 Bn | 43.79 Bn | - | 394.92 Mn |
| 8 | Incyte | 25.23 Bn | 20.69 Bn | 1.57 Bn | 516.95 Mn |
| 9 | United Therapeutics | 21.67 Bn | 19.01 Bn | 683.80 Mn | 146.30 Mn |
| 10 | Siga Technologies | 220.19 Mn | 65.22 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2025 | 7.05 Mn |
| Jun 30, 2025 | 4.40 Mn |
| Mar 31, 2025 | 3.46 Mn |
| Dec 31, 2024 | 3.34 Mn |
| Sep 30, 2024 | 3.02 Mn |
| Jun 30, 2024 | 2.89 Mn |
| Mar 31, 2024 | 3.05 Mn |
| Dec 31, 2023 | 2.62 Mn |
| Sep 30, 2023 | 3.65 Mn |
| Jun 30, 2023 | 5.12 Mn |
| Mar 31, 2023 | 5.05 Mn |
| Dec 31, 2022 | 6.41 Mn |
| Sep 30, 2022 | 5.73 Mn |
| Jun 30, 2022 | 6.84 Mn |
| Mar 31, 2022 | 3.55 Mn |
| Dec 31, 2021 | 2.14 Mn |
| Sep 30, 2021 | 3.24 Mn |
| Jun 30, 2021 | 2.26 Mn |
| Mar 31, 2021 | 2.30 Mn |
| Dec 31, 2020 | 3.01 Mn |